DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, recently announced the granting of stock options to a newly hired non-executive employee as part of their compensation package. On January 15, 2026, the company issued options to purchase a total of 50,000 shares of its common stock at an exercise price of $8.54 per share, reflecting the stock's closing price on the same date. This inducement aligns with Nasdaq Listing Rule 5635(c)(4) and was critical for the employee's acceptance of their role.

The options were authorized by DiaMedica's Compensation Committee and fall under the company's Amended and Restated 2021 Employment Inducement Incentive Plan. Vesting for the options is structured to occur cumulatively, with 25% becoming exercisable one year from the grant date and the remaining 75% vesting in 12 quarterly installments starting three months post the one-year anniversary, contingent on the employee remaining with the company. The options have a ten-year lifespan.

Founded with a mission to advance treatments for severe ischemic diseases, DiaMedica focuses on innovative therapies for conditions such as preeclampsia, fetal growth restriction, and acute ischemic stroke. Its lead drug candidate, DM199, represents the first synthetic version of the KLK1 protein and has been recognized as a therapeutic option for the treatment of these severe conditions, gaining traction in Asia.

For further insights, DiaMedica encourages interested parties to visit their official website at www.diamedica.com. The company's Chief Financial Officer Scott Kellen, Investor Relations’ Mike Moyer, and Media Contact Madelin Hawtin are also available for additional information.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is making strategic human resource moves, evidenced by its recent announcement regarding the grant of stock options to a newly hired non-executive employee under Nasdaq Listing Rule 5635(c)(4). This move not only reflects the company’s commitment to attracting talent but also signals confidence in its business direction and future prospects, particularly in the high-stakes arena of novel therapies for ischemic diseases and conditions like preeclampsia.

Investors should take note of the specific details surrounding the option grants, including the exercise price of $8.54, which aligns with the closing stock price on the grant date. This alignment demonstrates a prudent strategy to ensure that the interests of the employee and shareholders are linked, promoting a culture of shared success. The vesting schedule provides an incentive for long-term commitment, as the options are vested over a period of four years, which is common in the biotechnology sector. Such structures are designed to foster stability and continuity within the company, both of which are crucial for a clinical-stage firm.

Looking ahead, investors may want to examine DiaMedica's pipeline, particularly the progress of its lead candidate, DM199, which aims to capitalize on established therapeutic modalities. While potential remains for significant returns, investors must remain cognizant of the inherent risks associated with clinical trials and regulatory approvals, which are common hurdles in the biopharmaceutical sector.

In light of these developments, investors could consider maintaining or increasing their positions in DiaMedica, particularly if they have a long-term outlook on the stock. Given the company's focus on serious, underserved medical conditions, there may be substantial upside potential as clinical milestones are reached and validated. Thus, keeping an eye on pipeline developments and market reactions will be critical for effective investment decisions in the coming months.